←
Ke Cheng, Ph.D.177 posts
Ke Cheng, Ph.D. avatar

Ke Cheng, Ph.D.

@KeChengLab

Alan L. Kaganov Professor of Biomedical Engineering, Columbia University. Stem cells, biomaterials, and exosomes for regeneration. Views are mine.

◷ Joined April 2020▧ 35 Photos and videos
Ke Cheng, Ph.D. avatar
Ke Cheng, Ph.D.@KeChengLab·Sep 15

Excited to co-chair AAEV2026 this November with @SusmitaSahooPhD. We have a great line up of speakers and editors. Abstract submission and early bird registration deadline is approaching.

🌟 AAEV 2026 is coming to Jersey City! 🌟 Join us Nov 11–15, 2026 for an exciting program featuring renowned keynote & invited speakers, Co-Chairs Ke Cheng & Susmita Sahoo, and a special Editors’ Panel with editors from Nature Biomedical Engineering, Cell Stem Cell, and Nature Nanotechnology. 🧬 Cutting-edge EV science 🎤 Outstanding speakers 📝 Meet leading journal editors 🤝 Connect with the EV community 📍 Jersey City, NJ 📅 Nov 11–15, 2026 Don’t miss #AAEV2026! 🫧 aaev.org/2026-newyork #ExtracellularVesicles #EVs #Exosomes #EVResearch #AnnualMeeting

Post attachmentPost attachmentPost attachmentPost attachment
Ke Cheng, Ph.D. avatar
Ke Cheng, Ph.D.@KeChengLab·Oct 13

Many thanks to @NatureBiotech for selecting our work as the front cover. Congratulations again to @ShuoL_ and the entire team.

The October issue is live nature.com/nbt/volumes/44/is… On the cover, engineered inhalable exosomes display a bispecific T cell activator targeting a cancer cell along with a T cell. PD1 and FZD on the exosomes block tumor-cell PD-L1 signaling and neutralize tumor-secreted Wnt, respectively go.nature.com/496Ins7 rdcu.be/avnjBsFZKzFa

Post attachment
American Association of Extracellular Vesicles avatar
⟳ Ke Cheng, Ph.D. retweeted
American Association of Extracellular Vesicles@AAEV_org·Sep 16

📢 AAEV 2026 Deadline Extension! In response to requests from researchers, we’re extending the following deadlines from Sept 15 → Sept 25: 🐦 Early Bird Registration 📝 Abstract Submission 🏆 Award Nominations ⚠️ Abstract review begins this week. Late abstracts may still be accepted for poster presentations and remain eligible for poster awards, but may not be considered for oral presentations. Don’t miss the extended deadline—submit by Sept 25! #AAEV2026 #ExtracellularVesicles #EVs #AbstractSubmission #EarlyBird #ScientificConference ChatGPT can make mistakes. Workspace data isn't used to train models.

American Association of Extracellular Vesicles avatar
⟳ Ke Cheng, Ph.D. retweeted
American Association of Extracellular Vesicles@AAEV_org·Apr 27

We’re thrilled to announce that Dr. David Lyden (Weill Cornell Medicine) will deliver the Opening Plenary Lecture at the AAEV 2026 Annual Meeting! A pioneer of the pre-metastatic niche concept, Dr. Lyden’s groundbreaking work revealed how tumor-derived extracellular vesicles orchestrate systemic metastasis and organ-specific spread—reshaping our understanding of cancer biology. Join us to hear insights from a global leader whose discoveries span EV biology, metastasis, and translational biomarkers. #AAEV2026 #ExtracellularVesicles #CancerResearch #Metastasis

Post attachment
Ke Cheng, Ph.D. avatar
Ke Cheng, Ph.D.@KeChengLab·Apr 18

I am deeply grateful to all my mentees and mentors for the @aimbe professional impact award for mentoring. This mentoring award is because of you and for you.

Post attachmentPost attachment
Ke Cheng, Ph.D. avatar
Ke Cheng, Ph.D.@KeChengLab·Feb 28

Look forward to AAEV2026 in the neighborhood!

Save the Date: AAEV Annual Meeting | Nov 12–15, 2026 | NYC Metropolitan Area We are pleased to announce that the American Association of Extracellular Vesicles (AAEV) Annual Meeting will take place November 12–15, 2026 in The Westin Jersey City Newport in the New York City Metropolitan Area. Find more information: aaev.org/

Post attachment
Ke Cheng, Ph.D. avatar
Ke Cheng, Ph.D.@KeChengLab·5 Dec 2025

Huge congratulations to the Capricor team. Proud to have been part of the 1st academic IND in the early days, leading a young team out of a modest tissue-culture room. 16 years: from the first IND to this Phase 3 success - remarkable.

Breaking: Capricor is extremely pleased to announce positive topline results from our pivotal Phase 3 HOPE-3 clinical study evaluating Deramiocel in Duchenne muscular dystrophy. HOPE-3 met its primary endpoint and key cardiac secondary endpoint, with all Type 1 error–controlled secondary endpoints also achieving statistical significance. Deramiocel maintained a favorable safety and tolerability profile consistent with prior studies. We are grateful to the patients, families, investigators and partners who made this milestone possible. Read the full announcement: bit.ly/3Ko9KV6 Join our conference call and webcast today at 8:00 a.m. ET. bit.ly/48O3SOb $CAPR #Duchenne #DMD #Deramiocel #HOPE3 #CellTherapy #RareDiseaseAdvocate

Post attachment
Ke Cheng, Ph.D. avatar
Ke Cheng, Ph.D.@KeChengLab·25 Nov 2025

Honored to receive the AAEV Founder’s Award and to be inducted into the inaugural class of Fellow of AAEV at the 2025 @AAEV_org Annual Conference in Salt Lake City. Grateful to my team, collaborators, and the EV community for their support and commitment to advancing EV research.

Post attachmentPost attachmentPost attachmentPost attachment
Ke Cheng, Ph.D. avatar
Ke Cheng, Ph.D.@KeChengLab·20 Nov 2025

AAEV 2025 kicks off in just 2 hours !🎇🎇we look forward to seeing you at the U Utah Alumni House Salt Lake City 🏔️🏔️🏔️

Post attachmentPost attachmentPost attachmentPost attachment